Rajiv Agarwal, MD

Panelists discuss the current barriers to urine albumin-creatinine ratio (uACR) testing, strategies to address these barriers, the guideline goals for reducing uACR, and the importance of a multimodal approach, as well as how increased awareness of chronic kidney disease (CKD) testing can improve patient outcomes and engage health care providers in promoting testing.

Panelists discuss key updates in clinical guidelines for chronic kidney disease (CKD) testing in patients with type 2 diabetes, highlighting the latest recommendations for improving screening and diagnosis.

Panelists discuss the criteria for identifying at-risk patients for chronic kidney disease (CKD) testing in type 2 diabetes and review the screening and detection tests, emphasizing the critical importance of early detection through blood and urine tests for both CKD management and heart failure prevention.

Panelists discuss the prevalence of chronic kidney disease (CKD) in patients with type 2 diabetes and how CKD significantly impacts overall patient health.